Compare · DRIO vs RMD
DRIO vs RMD
Side-by-side comparison of DarioHealth Corp. (DRIO) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRIO and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $33.09B, about 619.6x DRIO ($53.4M).
- Over the past year, DRIO is down 62.6% and RMD is down 11.5% - RMD leads by 51.1 points.
- DRIO has been more active in the news (10 items in the past 4 weeks vs 9 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 5 for DRIO).
- Company
- DarioHealth Corp.
- ResMed Inc.
- Price
- -
- -
- Market cap
- $53.4M
- $33.09B
- 1M return
- -27.64%
- +4.60%
- 1Y return
- -62.63%
- -11.49%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 10
- 9
- Recent ratings
- 5
- 25
DarioHealth Corp.
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario Tools, which are devices that integrate with applications on a user's smartphone; DarioEngage, a population health management platform; and the Dario Loop, an AI-driven journey engine. It also sells device-specific disposables test strip cartridges, lancets, and Dario Blood Glucose Monitoring System; and Dario Smart Diabetes Management Solution, which includes tools to help diabetic patients manage their disease. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is based in New York, New York.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest DRIO
- DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs
- Director Shaked Yoav converted options into 772 shares and was granted 54,000 shares, increasing direct ownership by 167% to 87,582 units (SEC Form 4)
- Director Mcgrath Dennis M was granted 61,000 shares, increasing direct ownership by 220% to 88,737 units (SEC Form 4)
- Director Palumbo John R was granted 62,000 shares, increasing direct ownership by 1,378% to 66,500 units (SEC Form 4)
- Director Stern Adam K converted options into 20,195 shares and was granted 28,000 shares, increasing direct ownership by 94% to 57,717 units (SEC Form 4)
- Director Matheis Dennis was granted 44,000 shares, increasing direct ownership by 102% to 87,026 units (SEC Form 4)
- Chief Financial Officer Franco-Yehuda Chen was granted 95,000 shares, increasing direct ownership by 317% to 125,000 units (SEC Form 4)
- Director Karah Hila was granted 28,000 shares, increasing direct ownership by 90% to 58,965 units (SEC Form 4)
- Chief Executive Officer Raphael Erez converted options into 579 shares and was granted 297,000 shares, increasing direct ownership by 190% to 454,432 units (SEC Form 4)
- New insider Sherman Lara Ann claimed ownership of 120,000 shares (SEC Form 3)
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target